PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 5 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 5 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
BRIEF published on 12/13/2024 at 23:05, 1 year 5 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 5 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
BRIEF published on 11/11/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/11/2024 at 07:05, 1 year 6 months ago Relief Therapeutics rapporte des résultats positifs dans l'essai RLF-TD011 pour l'épidermolyse bulleuse THÉRAPEUTIQUE DE SECOURS RLF-TD011 Résultats Des Essais Cliniques Epidermolyse Bulleuse Diversité Du Microbiome
PRESS RELEASE published on 11/11/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/04/2024 at 07:05, 1 year 6 months ago Relief Therapeutics and Renexxion Consider Reverse Merger Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
BRIEF published on 11/04/2024 at 07:05, 1 year 6 months ago Relief Therapeutics et Renexxion envisagent une fusion inversée Biotechnologie Valeur Actionnariale Soins De Santé Fusion Inversée Troubles Gastro-intestinaux
PRESS RELEASE published on 11/04/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger Relief Therapeutics signs non-binding letter of intent with Renexxion for reverse merger, aiming to create a combined entity with an expanded therapeutic pipeline Biopharmaceutical Relief Therapeutics Therapeutic Pipeline Reverse Merger Renexxion
Published on 05/16/2026 at 01:15, 1 day 19 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 1 day 20 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 21 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/16/2026 at 16:08, 1 day 4 hours ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 2 days ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 2 days 2 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 2 days 5 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 5 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 10 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 11 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 2 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
